ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access